GRFS
Grifols SAPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 17 ▲ Grifols announced proof-of-concept data from its Chronos-PD program,…
- Mar 17 FDA: Grifols Shares Results From its Chronos Platform Identifyi…
- May 11 Trial readout: T-90d Trial Readout: Alpha-1 MP (Phase 3)
- May 20 Trial readout: T-90d Trial Readout: Alpha-1 MP (Phase 3)
- Jul 16 FDA: Grifols Doses First Patients in Two Phase 3 Trials to Expa…
- Aug 10 FDA: Grifols Announces Last Patient Last Visit in SPARTA, its P…
- Sep 30 ▼ Short interest jumps 105.0% to 7.00M
- Oct 1 Trial readout: Results Pending: Alpha-1 MP (Phase 3), Completed 86d ago
- Nov 2 ▲ Grifols reported Q3 2026 revenue of EUR 2,040 million (+8.4% cc), ne…
Signal stack
Where each data set points today.
- InstitutionsBULLISH
Q3 2026: 17 added (0 new), 7 trimmed or exited.
- AnalystsBULLISH
14 of 21 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −14.5% to 5.98M shares. 8.1 days to cover, ≈0.9% of shares.
- TrendUPTREND
12% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | ADD | $17.7M |
| UBS Group AG | ADD | $17.5M |
| BARCLAYS PLC | ADD | $8.4M |
| Hudson Bay Capital Management LP | DOUBLED | $7.9M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $5.2M |
| Verition Fund Management LLC | TRIM | $1.7M |
| Quantinno Capital Management LP | TRIM | $940.6K |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $926.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analystsPrice is below the lowest target. Median implies +19%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 26, 2026 | JP Morgan MAINTAIN | Neutral |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | None | None | No data | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
4 filings · 3 press releases · 1 bullish · 0 bearish · 3 neutral- NEUTRAL 6-KNov 2, 2026
Grifols' Board approved an interim dividend of €0.15 per share, payable on December 4, 2026. This…
The dividend is a routine interim distribution; no material impact on the stock is expected. Monitor future filings for full-year earnings and any changes to the dividend policy.
- BULLISH 6-KNov 2, 2026
Grifols reported Q3 2026 revenue of EUR 2,040 million (+8.4% cc), net profit of EUR 162 million…
Monitor the SPARTA Phase 3 alpha-1 antitrypsin topline results expected by end of Q4 2026, and the continued trajectory of albumin recovery in China. The deleveraging trend and free cash flow…
- NEUTRAL PRESS RELEASEAug 10, 2026
Grifols announced completion of the clinical portion (last patient, last visit) of its Phase 3…
No efficacy data released yet; the stock is unlikely to move until topline results in late 2026. Monitor for any early leaks or presentations at medical conferences. The SWIFT-SC subcutaneous…
- NEUTRAL 6-KJul 30, 2026
Grifols announced the resignation of independent director Iñigo Sánchez-Asiaín Mardones (Audit…
Monitor for any strategic shifts tied to the new Audit Committee Chair's background, but this filing alone does not warrant a trading response. Focus on upcoming earnings and the potential IPO of…
All GRFS filing & press-release reports (7)
- 6-K reportNov 2, 2026
- 6-K reportNov 2, 2026
- PRESS-RELEASE reportAug 10, 2026
- 6-K reportJul 30, 2026
- PRESS-RELEASE reportJul 16, 2026
- 6-K reportJun 18, 2026
- PRESS-RELEASE reportMar 17, 2026